Proteomics in graft-versushost disease and graftversus-leukemia - Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation - page 455

Table 19.1A Candidate Acute GVHD Biomarkers with Diagnostic and Prognostic Significance Identified Based
on GVHD Pathology

No. of
Patients
in Study

Biofluid
Source Method

Target
Organ Protein Reference Diagnosis Prognosis Predictive

ND Yes Yes

Albumin [69] Serum Chemical

assay

401 Systemic/

GI tract/
renal

CRP [56] Serum ELISA 96 Systemic Yes but also

increased in
other TRC

Yes Yes

[59] Serum ELISA 350 Systemic Yes but also

increased in
other TRC

ND Yes

CXCL10 [62] Serum Multiplex

fluorescence
bead-based
immunoassay

34 Systemic Yes ND Yes

461

HGF [63] Serum ELISA 38 Systemic Yes ND ND

[71] Plasma ELISA 826+ 128 * GI tract Yes Yes ND

IL-2R α [47] Serum ELISA 30 Systemic Yes ND Yes

[46] Serum ELISA 36 Systemic Yes but also

increased in
other TRC

ND Yes

[48] Serum ELISA 60 Systemic Yes ND No

[49] Serum ELISA 39 Systemic No ND Yes

[54] Plasma ELISA 62 Systemic ND ND Yes

IL-6 [57] Plasma ELISA 147 Systemic Yes ND Yes

[53] Serum ELISA 84 Systemic Yes but also

increased in
other com-
plications

Yes Yes

[59] Serum ELISA 350 Systemic Yes but also

increased in
other com-
plications

ND Yes

IL-8 [59] Serum ELISA 30 Systemic Yes ND ND

[53] Serum ELISA 84 Systemic Yes but also

increased in
other com-
plications

Yes Yes

IL-10 [93] Serum ELISA 46 Systemic Yes ND ND

IL-12 [60] Plasma ELISA 113 Systemic Yes ND ND

IL-18 [94] Serum ELISA 37 Systemic Yes ND No

[49] Serum ELISA 39 Systemic Yes ND Yes

KRT18 [64] Serum ELISA 55 GI tract Yes ND ND

[68] Serum ELISA 48 Systemic ND Yes ND

[71] Plasma ELISA 826+ 128 * GI tract Yes Yes ND

REG3 α [71] Plasma ELISA 826+ 128 * GI tract Yes Yes ND

(Continued)